SPR741 (TFA)

• UNSPSC Description:

  SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 TFA increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 TFA inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 TFA[1][2].

• Target Antigen:

  Antibiotic; Bacterial

• Type:

  Peptides

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/spr741-tfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(N[C@@H]([C@H](O)C)C(N[C@H](CO)C(N[C@@H](CCNC([C@](N1)([H])[C@H](O)C)=O)C(N[C@@H](CCN)C(N[C@@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCN)C1=O)=O)CCN)=O)CC(C)C)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O

• Molecular Weight:

  1106.15

• References & Citations:

  [1]Corbett D, et al. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00200-17.|[2]Eckburg PB, et al. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects. Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00892-19.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 1